{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:35:48Z","timestamp":1789983348776,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03707-5","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:02:13Z","timestamp":1707303733000},"page":"704-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis"],"prefix":"10.1007","volume":"84","author":[{"given":"Manila","family":"Rubino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Danilo","family":"Di Stasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Anna","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahila Esmeralda","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Iuliana","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Grana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"3","key":"3707_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2478\/enr-2019-0020","volume":"53","author":"FA Farrugia","year":"2019","unstructured":"F.A. Farrugia, A. Charalampopoulos, Pheochromocytoma. Endocr. Regul. 53(3), 191\u2013212 (2019).","journal-title":"Endocr. Regul."},{"issue":"1","key":"3707_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","volume":"38","author":"VL Martucci","year":"2014","unstructured":"V.L. Martucci, K. Pacak, Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr. Probl. Cancer 38(1), 7\u201341 (2014).","journal-title":"Curr. Probl. Cancer"},{"key":"3707_CR3","doi-asserted-by":"crossref","unstructured":"S. Jhawar, Y. Arakawa, S. Kumar, D. Varghese, Y.S. Kim, N. Roper, et al. New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications. Cancers (Basel). 14(3), 594 (2022).","DOI":"10.3390\/cancers14030594"},{"key":"3707_CR4","doi-asserted-by":"crossref","unstructured":"A. Cascon, B. Calsina, M. Monteagudo, S. Mellid, A. Diaz-Talavera, M. Curras-Freixes, et al. Genetic bases of pheochromocytoma and paraganglioma. J. Mol. Endocrinol. 70(3), e220167 (2023).","DOI":"10.1530\/JME-22-0167"},{"issue":"11","key":"3707_CR5","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H.R. Haak, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476\u20131490 (2020).","journal-title":"Ann. Oncol."},{"key":"3707_CR6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2022","unstructured":"M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. Fouchardiere, H.R. Haak, et al., Corrigendum to \u201cAdrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACANClinical Practice Guidelines for diagnosis, treatment and follow-up\u201d: [Annalsof Oncology volume]. Ann. Oncol. 31, 1476\u20131490 (2022).","journal-title":"Ann. Oncol."},{"issue":"9","key":"3707_CR7","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"O. Hamidi, W.F. Young Jr., N.M. Iniguez-Ariza, N.E. Kittah, L. Gruber, C. Bancos et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J. Clin. Endocrinol. Metab. 102(9), 3296\u20133305 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","volume":"23","author":"R Garcia-Carbonero","year":"2021","unstructured":"R. Garcia-Carbonero, F. Matute Teresa, E. Mercader-Cidoncha, M. Mitjavila-Casanovas, M. Robledo, I. Tena et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin. Transl. Oncol. 23(10), 1995\u20132019 (2021).","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"3707_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4158\/EP-2017-0057","volume":"24","author":"LB Mercado-Asis","year":"2018","unstructured":"L.B. Mercado-Asis, K.I. Wolf, I. Jochmanova, D. Taieb, Pheochromocytoma: a genetic and diagnostic update. Endocr. Pract. 24(1), 78\u201390 (2018).","journal-title":"Endocr. Pract."},{"issue":"4","key":"3707_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"L.T. van Hulsteijn, N.D. Niemeijer, O.M. Dekkers, E.P. Corssmit, (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. (Oxf.) 80(4), 487\u2013501 (2014).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"10","key":"3707_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1159\/000522089","volume":"112","author":"GD Di Stasio","year":"2022","unstructured":"G.D. Di Stasio, V. Cuccurullo, G.L. Cascini, C.M. Grana, Tailored molecular imaging of pheochromocytoma and paraganglioma: which tracer and when. Neuroendocrinology 112(10), 927\u2013940 (2022).","journal-title":"Neuroendocrinology"},{"issue":"4","key":"3707_CR12","first-page":"347","volume":"14","author":"L Bodei","year":"2010","unstructured":"L. Bodei, G. Pepe, G. Paganelli, Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med Pharm. Sci. 14(4), 347\u2013351 (2010).","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"5","key":"3707_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0737-9","volume":"33","author":"DJ Pinato","year":"2016","unstructured":"D.J. Pinato, J.R. Black, R. Ramaswami, T.M. Tan, D. Adjogatse, R. Sharma, Peptide receptor radionuclide therapy for metastatic paragangliomas. Med Oncol. 33(5), 47 (2016).","journal-title":"Med Oncol."},{"issue":"2","key":"3707_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med 376(2), 125\u2013135 (2017).","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"3707_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky, P. Brock et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 19(7), 839\u2013868 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"9","key":"3707_CR16","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"G. Kong, S. Grozinsky-Glasberg, M.S. Hofman, J. Callahan, A. Meirovitz, O. Maimon et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J. Clin. Endocrinol. Metab. 102(9), 3278\u20133287 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3707_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"V. Ambrosini, J. Kunikowska, E. Baudin, L. Bodei, C. Bouvier, J. Capdevila et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur. J. Cancer 146, 56\u201373 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"3707_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0484-y","volume":"9","author":"MP Yadav","year":"2019","unstructured":"M.P. Yadav, S. Ballal, C. Bal, Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 9(1), 13 (2019).","journal-title":"EJNMMI Res"},{"issue":"4","key":"3707_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","volume":"15","author":"L Urso","year":"2023","unstructured":"L. Urso, A. Nieri, L. Uccelli, A. Castello, P. Artioli, C. Cittanti, M.C. Marzola, L. Florimonte, M. Castellani, S. Bissoli, F. Porto, A. Boschi, L. Evangelista, M. Bartolomei, Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE. Pharmaceutics 15(4), 1110 (2023).","journal-title":"Pharmaceutics"},{"key":"3707_CR20","doi-asserted-by":"crossref","unstructured":"A.L. Marretta, A. Ottaiano, D. Iervolino, A. Bracigliano, O. Clemente, F. Di Gennaro, et al. Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis. J. Clin. Med. 12(4), 1494 (2023).","DOI":"10.3390\/jcm12041494"},{"key":"3707_CR21","doi-asserted-by":"publisher","first-page":"957172","DOI":"10.3389\/fendo.2022.957172","volume":"13","author":"S Prado-Wohlwend","year":"2022","unstructured":"S. Prado-Wohlwend, M.I. Del Olmo-Garcia, P. Bello-Arques, J.F. Merino-Torres, Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review. Front Endocrinol. (Lausanne) 13, 957172 (2022)","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"1","key":"3707_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","volume":"181","author":"WT Zandee","year":"2019","unstructured":"W.T. Zandee, R.A. Feelders, D.A. Smit Duijzentkunst, J. Hofland, R.M. Metselaar, R.A. Oldenburg et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur. J. Endocrinol. 181(1), 45\u201353 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"3707_CR23","doi-asserted-by":"crossref","unstructured":"A.R. Vyakaranam, J. Crona, O. Norlen, D. Granberg, U. Garske-Roman, M. Sandstrom, et al. Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE. Cancers (Basel). 11(7), 909 (2019).","DOI":"10.3390\/cancers11070909"},{"key":"3707_CR24","doi-asserted-by":"crossref","unstructured":"A. Kolasinska-Cwikla, M. Peczkowska, J.B. Cwikla, I. Michalowska, J.M. Palucki, L. Bodei, et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J. Clin. Med. 8(7), 952 (2019).","DOI":"10.3390\/jcm8070952"},{"issue":"4","key":"3707_CR25","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","volume":"6","author":"S Severi","year":"2021","unstructured":"S. Severi, A. Bongiovanni, M. Ferrara, S. Nicolini, F. Di Mauro, M. Sansovini et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open 6(4), 100171 (2021).","journal-title":"ESMO Open"},{"issue":"1","key":"3707_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"L. Bodei, M. Kidd, G. Paganelli, C.M. Grana, I. Drozdov, M. Cremonesi et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur. J. Nucl. Med Mol. Imaging 42(1), 5\u201319 (2015).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"issue":"5","key":"3707_CR27","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","volume":"49","author":"MP Yadav","year":"2022","unstructured":"M.P. Yadav, S. Ballal, R.K. Sahoo, C. Bal, Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur. J. Nucl. Med Mol. Imaging 49(5), 1595\u20131606 (2022).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03707-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T06:24:01Z","timestamp":1715063041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03707-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L.B.: nonremunerated consultancy for AAA-Novartis, Ipsen, ITM, Great Point Partners, RayzeBio, Point Biopharma; research grant AAA-Novartis. The other authors have no relevant financial or non-financial interests to disclose regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was granted by the Ethics Committee (UID 2197).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A waiver of specific consent was granted due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}